Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Our Initiatives
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the national flag of Canada alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share

Our Approach to Climate Action

Colbeck’s Corner wind farm in Carson County, Texas, provides the equivalent of more than 60% of Johnson & Johnson’s electricity use in the U.S.

s a healthcare company, Johnson & Johnson understands that climate health can affect human health. In fact, we’re seeing climate change impact health in new ways by changing infectious disease patterns and increasing the risk of drought and food insecurity. We have taken sustained, long-term action to reduce our greenhouse gas (GHG) emissions and we are encouraging our suppliers to do the same. We also work with like-minded partners to advance solutions at the intersection of human health and environmental health, and we support responsible climate and energy policy around the world.

The latest climate science indicates rising global temperatures must be limited to 1.5°C to avoid the most significant impacts of climate change to human and planetary health. To do our part to help maintain a healthy climate, we’ve set our most ambitious climate goals to date, building on our past achievements while accelerating future actions.

  • By 2025, source 100% of our electricity needs from renewable sources.
  • By 2030, achieve carbon neutrality for our operations, going beyond our Science-Based Target to reduce absolute Scope 1 and 2 emissions 60% from 2016 levels.
  • By 2030, reduce absolute upstream value chain (Scope 3) emissions 20% from 2016 levels. Reaching this goal will deliver nearly 2.5 times the carbon footprint reduction compared to that of our own operations.

Our operational emissions goal has been validated by the Science-Based Targets initiative (SBTi) as being consistent with the reductions required to keep global warming to 1.5°C, and our value chain (Scope 3) goal meets the SBTi’s criteria for ambitious value chain goals.

We are also proud signatories of the Race to Zero/ Business Ambition for 1.5 campaign and have an ambition to achieve net zero carbon emissions across our value chain by 2045.

How We Will Reach Our Goals

expand

Advocating for Climate-Friendly Policies

For many years, we’ve participated in coalitions that publicly support actions to promote a low carbon economy and mitigate climate change at scale. For example, we work with other companies and organizations through the Renewable Energy Buyers Alliance and the Climate Leadership Council to share best practices and advocate for the advancement of renewable energy and market-based climate policies. Additionally, we have supported the Paris Climate Agreement through various platforms such as the ‘We Are Still In/America Is All In' campaign, and we were proud to join other companies and investors in signing an open letter to President Biden calling for an ambitious U.S. emissions reduction target.

Our Commitment to Energy Leadership

Highlights from Johnson & Johnson's 30 years of energy innovation and leadership.

1986

Established formal energy management program

2000

Established first enterprise-wide public commitment to reduce CO2 emissions based on Kyoto Protocol

2005

Developed internal CO2 capital relief program, which has resulted in 231 projects and 288,000 metric tons of CO2 saved per year over the past 15 years

2010

Announced goal to reduce CO2 emissions by 20% by 2020 and increase on-site clean energy capacity to 50MW by 2015. Currently over 50 solar arrays and 4 wind turbines built, totaling 56MWs on our properties globally

2015

Supported the UNFCCC Paris Climate agreement and committed to using 100% renewable electricity in our operations by joining RE100. Since then increased our renewable electricity consumption to near 50%

2020

Launched 4th generation science-based climate commitments, accelerating our 100% renewable electricity commitment to 2025, committing to carbon neutrality in our operations and a 20% value chain emissions reduction by 2030

1986

2000

2005

2010

2015

2020

We believe continual improvement of our ESG management practices helps drive long-term value creation and strengthens our ability to respond to the needs and expectations of all stakeholders.

More From Johnson & Johnson

Cautionary Note Regarding Forward-Looking Statements: This page contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company’s ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global healthcare reforms; trends toward healthcare cost containment; changes in behavior and spending patterns of purchasers of healthcare products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the healthcare industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” in the Company’s most recently filed Quarterly Report on Form 10-Q and the Company’s subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made on this page speaks only as of the date presented. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments. Third-party trademarks used herein are trademarks of their respective owners.

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue